Avenue Therapeutics, Inc. (ATXI) Social Stream



Avenue Therapeutics, Inc. (ATXI): $3.63

0.07 (+1.97%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

AVENUE THERAPEUTICS INC (ATXI) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering ATXI.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2023-04-03 1 $32 $32 $32 $0.19 16742.11%
NA 1 $NA $NA $NA $0.19 NA%

Price Target Last Issued NA NA, NA

The Trend in the Analyst Price Target


Over the past 21 months, ATXI's average price target has gone up $20.

500 - Internal server error

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-04-03 1 32 32 32 1.18 2611.86%

ATXI Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 1 0 0 0 0 1

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • In terms of how AVENUE THERAPEUTICS INC fares relative to all US stocks, note that its number of analysts covering the stock is higher than practically none of that group.
  • In terms of how AVENUE THERAPEUTICS INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than just about 100% of that group.
  • ATXI has a higher upside potential (average analyst target price relative to current price) than 99.89% of Healthcare stocks.
  • ATXI has a higher average analyst price target than 92.17% of stocks in the micro market cap category.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to AVENUE THERAPEUTICS INC are NRBO, MBRX, and ENLV.

Is ATXI a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!